# Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)

> **NCT05001698** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 15 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Anifrolumab

## Key facts

- **NCT ID:** NCT05001698
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-27
- **Primary completion:** 2022-06-02
- **Final completion:** 2022-06-02
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05001698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05001698, "Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05001698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*